Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration

Published on November 17th, 2022


As part of our collaboration with University of Cambridge, University of Zurich, Mayo Clinic, Fred Hutchinson Cancer Research Center, Yale University, and Howard Hughes Medical Institute, the paper presents a new approach, enabling rapid and highly accurate analysis of complex immune reactions which offers the opportunity for faster, better and cheaper development of medicines for multiple diseases.

Serological fingerprinting reveals both the quality and the quantity of antibodies produced by the immune system against a pathogen. Information that is crucial for truly understanding the functional immune response but is not provided by established antibody tests.
Currently, investigating the immune response includes serological titer-based virus neutralization assays and in-vitro ELISA tests. While these titer assays are well established, they are often tedious to optimize, susceptible to non-specific binding, and are difficult to compare between laboratories. Most importantly, titers cannot independently provide information on the binding affinity and concentration of serum antibodies both of which are crucial when researchers evaluate the activity of drugs such as monoclonal antibodies.

The paper outlines a new way of linking monoclonal antibody affinities with their antiviral activity and serological fingerprints, which has the potential to guide the development of new therapeutics to fit the affinity window of antibodies generated by the humoral immune response.

Instrument: Fluidity One-M
Therapeutic area: Covid-19

A full list of recent publications in which our technology has been applied can be accessed here.